This company has been marked as potentially delisted and may not be actively trading. Millendo Therapeutics (MLND) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock MLND vs. RGLS, GHRS, TYRA, MRVI, SVRA, KURA, URGN, SBTX, UPB, and ETONShould you be buying Millendo Therapeutics stock or one of its competitors? The main competitors of Millendo Therapeutics include Regulus Therapeutics (RGLS), GH Research (GHRS), Tyra Biosciences (TYRA), Maravai LifeSciences (MRVI), Savara (SVRA), Kura Oncology (KURA), UroGen Pharma (URGN), Silverback Therapeutics (SBTX), Upstream Bio (UPB), and Eton Pharmaceuticals (ETON). These companies are all part of the "medical" sector. Millendo Therapeutics vs. Regulus Therapeutics GH Research Tyra Biosciences Maravai LifeSciences Savara Kura Oncology UroGen Pharma Silverback Therapeutics Upstream Bio Eton Pharmaceuticals Millendo Therapeutics (NASDAQ:MLND) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking. Does the media refer more to MLND or RGLS? In the previous week, Regulus Therapeutics had 4 more articles in the media than Millendo Therapeutics. MarketBeat recorded 4 mentions for Regulus Therapeutics and 0 mentions for Millendo Therapeutics. Regulus Therapeutics' average media sentiment score of 0.73 beat Millendo Therapeutics' score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Millendo Therapeutics Neutral Regulus Therapeutics Positive Does the MarketBeat Community believe in MLND or RGLS? Regulus Therapeutics received 494 more outperform votes than Millendo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformMillendo TherapeuticsN/AN/ARegulus TherapeuticsOutperform Votes49463.33% Underperform Votes28636.67% Which has stronger valuation and earnings, MLND or RGLS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMillendo TherapeuticsN/AN/A-$36.41MN/AN/ARegulus TherapeuticsN/AN/A-$30.04M-$0.73-10.81 Which has more volatility & risk, MLND or RGLS? Millendo Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500. Is MLND or RGLS more profitable? Regulus Therapeutics' return on equity of -53.07% beat Millendo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Millendo TherapeuticsN/A -91.03% -72.44% Regulus Therapeutics N/A -53.07%-48.58% Do analysts rate MLND or RGLS? Regulus Therapeutics has a consensus price target of $8.50, indicating a potential upside of 7.73%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Regulus Therapeutics is more favorable than Millendo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Millendo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Regulus Therapeutics 0 Sell rating(s) 5 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.29 Do institutionals and insiders hold more shares of MLND or RGLS? 92.4% of Regulus Therapeutics shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryRegulus Therapeutics beats Millendo Therapeutics on 12 of the 12 factors compared between the two stocks. Get Millendo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLND and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLND vs. The Competition Export to ExcelMetricMillendo TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$118.64M$6.45B$5.33B$8.31BDividend YieldN/A2.63%5.27%4.10%P/E RatioN/A8.3726.8319.59Price / SalesN/A258.36396.30135.08Price / CashN/A65.8538.3234.62Price / Book3.506.416.764.50Net Income-$36.41M$143.73M$3.24B$248.65M Millendo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLNDMillendo TherapeuticsN/A$6.23-1.0%N/A+96.0%$118.64MN/A0.0012Gap DownRGLSRegulus Therapeutics1.1696 of 5 stars$7.86-0.1%$8.50+8.1%+310.9%$520.67MN/A-7.3530GHRSGH Research2.3973 of 5 stars$9.98-1.8%$30.43+204.9%-16.2%$519.24MN/A-12.6310Analyst DowngradeTYRATyra Biosciences1.6443 of 5 stars$9.74-5.1%$30.83+216.6%-45.4%$517.10MN/A-6.0520News CoveragePositive NewsAnalyst ForecastAnalyst RevisionGap DownMRVIMaravai LifeSciences3.9769 of 5 stars$2.02-5.0%$6.22+208.6%-79.4%$512.49M$259.19M-1.23610SVRASavara1.6326 of 5 stars$2.95-2.3%$8.83+199.4%-31.9%$509.61MN/A-6.86N/ANews CoverageGap DownKURAKura Oncology4.2904 of 5 stars$5.81-4.6%$23.89+311.2%-73.7%$503.00M$67.99M-2.46130URGNUroGen Pharma3.9867 of 5 stars$10.63-4.6%$32.86+209.1%-67.4%$490.12M$90.40M-3.37200Trending NewsAnalyst DowngradeAnalyst RevisionGap DownSBTXSilverback TherapeuticsN/A$13.44-0.4%N/A+62.6%$484.62MN/A-5.5583High Trading VolumeUPBUpstream Bio1.9012 of 5 stars$8.98-5.5%$56.50+529.2%N/A$483.07M$2.30M0.0038Gap DownETONEton Pharmaceuticals2.3763 of 5 stars$17.28-0.4%$27.67+60.1%+450.3%$463.42M$39.01M-78.5520Positive News Related Companies and Tools Related Companies RGLS Alternatives GHRS Alternatives TYRA Alternatives MRVI Alternatives SVRA Alternatives KURA Alternatives URGN Alternatives SBTX Alternatives UPB Alternatives ETON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLND) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored52 Money Mondays for $7 (This Weekend Only)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Millendo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Millendo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MLND Stock Free MLND Stock Alerts